HEMATOLOGY, vol.12, no.6, pp.497-503, 2007 (Journal Indexed in SCI)
Article / Article
Title of Journal :
multidrug resistance, BCR/ABL, imatinib mesylate, chronic myeloid leukemia, Meg-01 cell line, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE, INHIBITION, APOPTOSIS, MESYLATE, THERAPY, EXPRESSION, CERAMIDE, PROTEINS, CANCER
A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib, which has shown striking activity in the chronic phase and the accelerated phase, but less so in the blast phase of the disease. Despite high rates of hematologic and cytogenetic responses to therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of patients with CML.